Hims & Hers Health says it is planning to sell compounded peptides. In a Monday earnings call, CEO Andrew Dudum described the company’s effort as a “best-in-class peptides experience,” including U.S.-manufactured products, clinical-led guidance, and ongoing blood testing.
The outlets also frame the announcement as part of Hims & Hers’ broader strategy to expand its offerings beyond its existing telehealth and at-home wellness services. While the reporting focuses on the planned peptides experience, sources emphasize that Hims & Hers is still developing the product and service components rather than stating that sales have already begun. The specific regulatory pathway or timing for launch is not detailed in the provided excerpts.
Overall, the coverage centers on the company’s stated plans—what it intends to offer (compounded peptides), how it intends to deliver them (U.S. manufacturing, clinical guidance, and blood testing), and that the effort is in development, according to the quoted remarks.
